The Initial and Midterm Clinical Outcome of Paclitaxel-eluting-stent (Zilver PTX) for the Femoropopliteal Arteries

The Initial and Midterm Clinical Outcome of Paclitaxel-eluting-stent (Zilver PTX) for the Femoropopliteal Arteries

We investigated the initial and midterm outcomes of Zilver PTX, which was approved in Japan for the first time. Patient population was the all-comer (71 patients, 81 limbs), which included 54.3% on hemodialysis, 58% of severe calcification, 61.7% of TASC D lesions and average lesion length was 204.7...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Myakkangaku = The Journal of Japanese College of Angiology 2014, Vol.54(10), pp.159-166
Hauptverfasser: Shiigai, Masaru, Miyamoto, Akira, Hakamata, Naohiro, Fukuda, Masahiro, Yamauchi, Yasutaka, Akita, Takako, Kuhara, Ryouji, Tezuka, Shingo
Format: Artikel
Sprache:eng ; jpn
Schlagworte:
drug eluting stent
femoropopliteal lesion
Zilver PTX
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We investigated the initial and midterm outcomes of Zilver PTX, which was approved in Japan for the first time. Patient population was the all-comer (71 patients, 81 limbs), which included 54.3% on hemodialysis, 58% of severe calcification, 61.7% of TASC D lesions and average lesion length was 204.7 ± 97.7 mm. MALE free ratios revealed 85.1% at 6 months and 70.1% at 1 year. Considering the study population which involved more than 50% of TASC D and hemodialysis patients, the initial and midterm clinical outcomes of Zilver PTX were feasible enough.
ISSN:0387-1126
1880-8840
DOI:10.7133/jca.14-00027